Dyne Therapeutics Appoints Vikram Karnani to Board

Dyne Therapeutics ( (DYN) ) has provided an update.

On December 22, 2025, Dyne Therapeutics, Inc.’s board of directors elected Vikram Karnani as an independent Class II director, with a term running until the company’s 2028 annual meeting of stockholders, signaling continued attention to board independence and governance. Karnani will receive standard non-employee director compensation, including an option to purchase 59,665 shares at $20.78 per share vesting over three years, annual cash and equity compensation, and reimbursement of board-related expenses, with no related-party relationships or transactions disclosed and with his role governed by the company’s standard indemnification agreement.

The most recent analyst rating on (DYN) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on Dyne Therapeutics stock, see the DYN Stock Forecast page.

Spark’s Take on DYN Stock

According to Spark, TipRanks’ AI Analyst, DYN is a Neutral.

Dyne Therapeutics’ stock score reflects its current financial health as a pre-revenue biotech, burdened by losses but supported by a strong balance sheet and recent strategic leadership changes. Technical indicators suggest bearish trends, yet the potential for future breakthroughs could alter its trajectory.

To see Spark’s full report on DYN stock, click here.

More about Dyne Therapeutics

Dyne Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies, operating within the life sciences sector and listed on the Nasdaq Stock Market, where it adheres to Nasdaq’s corporate governance and independence standards for its board of directors.

Average Trading Volume: 2,979,664

Technical Sentiment Signal: Buy

Current Market Cap: $3.21B

See more data about DYN stock on TipRanks’ Stock Analysis page.